Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases

Vaccine

Volumn 32, Issue 47, 2014, Pages 6177-6182

  Liu, Chia Chyi ^a   Chow, Yen Hung ^a   Chong, Pele ^a,b   Klein, Michel ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c VaxiBio Inc   (Canada)

Author keywords

Coxsackievirus, Inactivated whole virion vaccine; Cross neutralizing antibody; Enterovirus 71; Hand, foot and mouth diseases; Human enterovirus A (HEV A); Immunodominant epitopes; Serum free culture technology; Waning immunity

Indexed keywords

BIVALENT COXSACKIE16 VACCINE; BIVALENT ENTEROVIRUS 71 VACCINE; EV71 VACCINE; INACTIVATED VIRUS VACCINE; MULTIVALENT HAND FOOT AND MOUTH DISEASE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); COXSACKIE VIRUS; COXSACKIE VIRUS INFECTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG POTENCY; ECONOMIC ASPECT; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; HAND FOOT AND MOUTH DISEASE; HUMAN; IMMUNOASSAY; INFECTION PREVENTION; MEDICAL ETHICS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; VACCINATION; VACCINE PRODUCTION; VIRUS INFECTION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; ASIA; BLOOD; CROSS PROTECTION; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; HAND, FOOT AND MOUTH DISEASE; IMMUNOLOGY; MOLECULAR GENETICS; SERODIAGNOSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ASIA; CLINICAL TRIALS AS TOPIC; CROSS PROTECTION; ENTEROVIRUS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; HAND, FOOT AND MOUTH DISEASE; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 84907974648     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.064     Document Type: Review

References (43)

1. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26:91-107.
2. Solomon T., Lewthwarte P., Perera D., Cordosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis and control of enterovirus 71. Lancet Infect Dis 2010, 10:778-790.
3. Lee M.S., Tseng F.C., Chi C.Y., Wang J.R., Chong P., Su I.J. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012, 6(8):e1737.
4. McMinn P.C. Enterovirus vaccines for an emerging cause of brain-stem encephalitis. N Engl J Med 2014, 370:792-794.
5. Mao Q., Wang Y., Yao X., Bian L., Wu X., Xu M., et al. Coxsackievirus A16: epidemiology, diagnosis and vaccine. Hum Vaccines Immunother 2014, 10:360-367.
6. Yip C.C.Y., Lau S.K.P., Woo P.C.Y., Yuen K.Y. Human enterovirus 71 epidemics: what's next?. Emerg Health Threats J 2013, 6:19780. (Epub 2013, Sep 10).
7. Chan Y.F., Sam I.C., Abubakar S. Phylogenetic designation of EV71 genotypes and subgenotypes using complete genome sequences. Infect Genet Evol 2010, 10:404-412.
8. Huang S.W., Hsu Y.W., Smith D.J., Kiang D., Tsai H.P., Lin K.H., et al. Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008. J Clin Microbiol 2009, 47:3653-3662.
9. Bessaud M., Razafindratsimandresy R., Nougairede A., Joffret M.L., Deshpande J.M., Dubot-Peres A., et al. Molecular comparison and evolutionary analysis of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS One 2014, 9(3):e90624.
10. Liang Z.L., Mao Q., Gao F., Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2013, 7(1):111-121.
11. Plotkin S.A., Vidor E. Poliovirus vaccine-inactivated. Vaccine 2004, 625-649. WB Saunder Co., Philadelphia, PA. 4th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
12. Chong P., Hsieh S.Y., Liu C.C., Chou A.H., Chang J.Y., Wu S.C., et al. Production of EV71 vaccine candidates. Hum Vaccines Immunother 2012, 8:1-9.
13. Cheng A., Fung C.P., Liu C.C., Lin Y.T., Tsai H.Y., Chang S.C., et al. A phase 1, randomized, open-label study to evaluate the safety and immunogenicity of enterovirus 71 vaccine. Vaccine 2013, 31:2471-2476.
14. Chou A.H., Liu C.C., Chang J.Y., Jiang R., Hsieh Y.C., Tsao A., et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody responses against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS One 2013, 8(11):e79783.
15. Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014, 370:818-828.
16. Mao Q., Cheng T., Zhu F., Li J., Wang Y., Li Y., et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy Chinese infants and children. PLoS One 2013, 8:e79599.
17. Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., et al. An inactivated enterovirus 71 vaccine in health children. N Engl J Med 2014, 370:829-837.
18. Li J.X., Mao Q.Y., Liang Z.L., Ji H., Zhu F.C. Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials. Expert Rev Vaccines 2014, 13:609-618.
19. Zhu F.C., Meng F.Y., Li J.X., Li J.X., Li X.L., Mao Q.Y., et al. Efficacy, safety and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381:2024-2032.
20. Chen Y.J., Meng F.Y., Mao Q.Y., Li J.X., Wang H., Liang Z.L., et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large scale phase 3 clinical trial. Hum Vaccines Immunother 2014, 105:1366-1372.
21. Chen C.W., Lee Y.P., Wang Y.F., Yu C.K. Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine. Vaccine 2011, 29:2772-2776.
22. Wang S., Li J., Liang Z., Li X., Mao Q., Meng F., et al. A booster dose of an inactivated enterovirus 71 vaccine in Chinese young children: a randomized, double-blind, placebo-controlled clinical trial. J Infect Dis 2014, 10.1093/infdis/jiu113.
23. Liu V.V., Wu S., Xiong Y., Li T., Wen Z., Yan M., et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot and mouth disease in central China. PLoS One 2014, 9(4):e96051.
24. Chong P., Guo M.S., Lin F.H., Hsiao K.N., Weng G.S.Y., Chou A.H., et al. Immunological and biochemical characterization of coxsackievirus A16 viral particles. PLoS One 2012, 7(11):e49973.
25. Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liu S.J., Chang J.Y., et al. Identification and characterization of a cross-neutralization epitope of EV71. Vaccine 2011, 29:4362-4373.
26. Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits a balanced protective immunity against both viruses. Vaccine 2014, 32:2406-2412.
27. Lin C.W., Liu C.C., Lu T.C., Liu S.J., Chow Y.H., Chong P., et al. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems. Biomed Res Int 2014, http://dx.doi.org/10.1155/2014/670506.
28. Fujimoto T., Lizuka S., Enomoto M., Abe K., Yamashita K., Hanaoka N., et al. Hand, foot and mouth disease caused by coxsackievirus A6, Japan, 2011. Emerg Infect Dis 2012, 18:337-339.
29. Feder H.M., Bennett N., Modlin J.F. Atyptical hand, foot, and mouth disease: a vesiculobullous eruption caused by coxsackievirus A6. Lancet Infect Dis 2014, 14:83-86.
30. Chang L.Y., King C.C., Hsu K.H., Ning H.C., Tsao K.C., Li C.C., et al. Risk factors of enterovirus 71 infection and associated hand, foot and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002, 109(6):e88.
31. Yamayoshi S., Yamashita Y., Li J., Hanagata N., Minowa T., Takemura T., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med 2009, 15:798-801.
32. Lu Q.B., Zhang X.A., Wo Y., Xu H.M., Li X.J., Wang X.J., et al. Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009-2011. PLoS One 2012, 7(12):e52073.
33. Yamayoshi S., Iizuka S., Yamashita T., Minagawa H., Mizuta K., Okamoto M., et al. Human SCARB2-dependent infection by Coxsackievirus A7, A14 and A16 and enterovirus 71. J Virol 2012, 86:5686-5696.
34. Hu Y.F., Yang F., Du J., Dong J., Zhang T., Wu Z.Q., et al. Complete genome analysis of coxsackievirus A2, A4, A5, and A10 strains isolated from hand, foot, and mouth disease patients in China revealing frequent recombination of human enterovirus A. J Clin Microbiol 2011, 49(7):2426-2434.
35. Zhang T., Du J., Xue Y., Su H., Yang F., Jin Q. Epidemics and frequent recombination within species in outbreaks of human enterovirus B-associated hand, foot and mouth disease in Shandong China in 2010 and 2011. PLoS One 2013, 8:e67157.
36. Liu C.C., Chang H.W., Yang G., Chiang J.R., Chow Y.H., Sai I.H., et al. Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process. J Virol Methods 2011, 176:60-68.
37. Liu C.C., Chou A.H., Lien S.P., Lin H.Y., Liui S.J., Chang J.Y., et al. Identification and characterization of a cross-neutralization epitope of EV71. Vaccine 2011, 29:4362-4373.
38. Wang Y.F., Yu C.K. Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 2014, 21:31-41.
39. Lin Y.W., Yu S.L., Shao H.Y., Lin H.Y., Liu C.C., Hsiao K.N., et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 2013, 8(2):e57591.
40. Fujii K., Nagata N., Sato Y., Ong K.C., Wong K.T., Yamayoshi S., et al. Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. Proc Natl Acad Sci USA 2013, 110:14753-14758.
41. Chang H.W., Lin Y.W., Ho H.M., Lin M.H., Liu C.C., Shao H.Y., et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One 2013, 8:269858.
42. Liu C.C., Guo M.S., Lin F.H.Y., Hsiao K.N., Chang K.H., Chou A.H., et al. Purification and characterization of EV71 viral particles produced from Vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 2011, 6(5):e200005.
43. Lee B.Y., Wateska A., Bailey R.R., Tai J.H.Y., Bacon K.M., Smith K.J. Forecasting the economic value of an enterovirus 71 (EV71) vaccine. Vaccine 2010, 28:7731-7736.